Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Boston Scientific Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $64.5B | |
|---|---|---|
| Revenue (ttm) | 21.1B | |
| Net income (ttm) | 3.5B | |
| EPS (ttm) | $2.37 | |
| Shares out | 1.4B | |
| P/E (trailing) | 17.8x | |
| P/E (forward) | 13.2x | |
| Volume | 66,508,095 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B | +14.0% |
| Gross profit | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B | +14.1% |
| Operating income | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B | +31.8% |
| Net income | $1.04B | $698.0M | $1.59B | $1.85B | $2.89B | +29.1% |
| EPS (diluted) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | +29.5% |
| EBITDA | $2.52B | $2.74B | $3.45B | $3.94B | $5.10B | +19.3% |
| R&D | $1.20B | $1.32B | $1.41B | $1.62B | $2.05B | +14.3% |
| SG&A | $4.36B | $4.52B | $5.19B | $5.98B | $6.89B | +12.1% |
Recent company headlines from major financial publishers.
In the bull case, rapid clinical adoption of pulsed field ablation in international territories outpaces expectations, while FARAPULSE Ultra and ICE achieve broad commercial availability ahead of schedule in early 2027. Standalone WATCHMAN volume contraction reverses quickly as clinical education programs and 3-year CHAMPION trial data reassure physicians,. Annual diluted EPS growth reaches 14.5% to 15.0%, and operating margins expand toward top-tier peer levels.
The base case models management's updated FY2026 organic revenue guidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.0% | $73.0 | $75.7 | $78.6 | $82.0 | $85.9 |
| 7.5% | $67.2 | $69.3 | $71.6 | $74.2 | $77.1 |
| 8.0% | $62.5 | $64.1 | $65.9 | $68.0 | $70.2 |
| 8.5% | $58.5 | $59.8 | $61.3 | $62.9 | $64.7 |
| 9.0% | $55.1 | $56.2 | $57.4 | $58.7 | $60.1 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
